Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2012-2018: Deal trends, players, financials and forecasts

Publisher Name :
Date: 01-Apr-2018
No. of pages: 300
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

Summary

The Global Cancer Monoclonal Antibody Partnering 2012-2018: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in cancer monoclonal antibody partnering deals

Most active companies in cancer monoclonal antibody partnering

Disclosed headlines, upfronts, milestones and royalties by stage of development

Cancer monoclonal antibody partnering contract documents

Top cancer monoclonal antibody deals by value

This report provides details of the latest Cancer monoclonal antibody agreements announced in the healthcare sectors.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

Monoclonal antibodies

Murine mAb

Chimeric mAb

Humanized mAb

Human aAb

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all Cancer monoclonal antibody partnering deals announced since Jan 2012, including financial terms where available, including links to online deal records of actual Cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of Cancer monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Cancer monoclonal antibody dealmaking since 2012, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Cancer monoclonal antibody deals since 2012. Deals are listed by headline value, signed by big pharma, most active Cancer monoclonal antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of Cancer monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Cancer monoclonal antibody partnering deals signed and announced since Jan 2012, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Cancer monoclonal antibody partnering deals signed and announced since Jan 2012. The chapter is organized by specific Cancer monoclonal antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Cancer monoclonal antibody partnering company A-Z, deal type definitions and Cancer monoclonal antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Cancer monoclonal antibody partnering and dealmaking since 2012.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer monoclonal antibody technologies and products.

Key benefits

Global Cancer Monoclonal Antibody Partnering Terms & Agreements provides the reader with the following key benefits:

In-depth understanding of cancer monoclonal antibody deal trends since 2012

Access to headline, upfront, milestone and royalty data

Access to the structure of cancer monoclonal antibody agreements with numerous real life case studies

Comprehensive access to over 360 actual cancer monoclonal antibody deals entered into by the world's biopharma companies

Identify most active companies in cancer monoclonal antibody partnering

Insight into the terms included in a cancer monoclonal antibody agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Spot the emerging companies in the cancer monoclonal antibody area

Report scope

Global Cancer Monoclonal Antibody Partnering Terms & Agreements is intended to provide the reader with an in-depth understanding and access to cancer monoclonal antibody trends and structure of deals entered into by leading companies worldwide.

Cancer Monoclonal Antibody Partnering Terms & Agreements includes:

Trends in cancer monoclonal antibody dealmaking in the biopharma industry since 2012

Analysis of cancer monoclonal antibody deal structure

Access to headline, upfront, milestone and royalty data

Access to over 360 cancer monoclonal antibody deal records

The leading cancer monoclonal antibody deals by value since 2012

In Cancer Monoclonal Antibody Partnering Terms & Agreements, the available deals are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific oncology therapy target

Monoclonal antibody type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Cancer Monoclonal Antibody Partnering Terms & Agreements report provides comprehensive access to available deals and contract documents for over 360 cancer monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2012-2018: Deal trends, players, financials and forecasts

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Cancer monoclonal antibody dealmaking
2.1. Introduction
2.2. Cancer monoclonal antibody partnering over the years
2.3. Most active Cancer monoclonal antibody dealmakers
2.4. Cancer monoclonal antibody partnering by deal type
2.5. Cancer monoclonal antibody partnering by therapy area
2.6. Deal terms for Cancer monoclonal antibody partnering
2.6.1 Cancer monoclonal antibody partnering headline values
2.6.2 Cancer monoclonal antibody deal upfront payments
2.6.3 Cancer monoclonal antibody deal milestone payments
2.6.4 Cancer monoclonal antibody royalty rates

Chapter 3 - Leading Cancer monoclonal antibody deals
3.1. Introduction
3.2. Top Cancer monoclonal antibody deals by value

Chapter 4 - Most active Cancer monoclonal antibody dealmakers
4.1. Introduction
4.2. Most active Cancer monoclonal antibody dealmakers
4.3. Most active Cancer monoclonal antibody partnering company profiles

Chapter 5 - Cancer monoclonal antibody contracts dealmaking directory
5.1. Introduction
5.2. Cancer monoclonal antibody contracts dealmaking directory

Chapter 6 - Cancer monoclonal antibody dealmaking by technology type
Monoclonal antibodies
Chimeric mAb
Humanized mAb
Human mAb
Murine mAb

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices
Appendix 1 - Cancer monoclonal antibody deals by company A-Z
Appendix 2 - Cancer monoclonal antibody deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
Appendix 3 - Cancer monoclonal antibody deals by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Loan
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Appendix 4 - Cancer monoclonal antibody deals by therapy area
Appendix 5 -Deal type definitions

Current Partnering

List of Figures

Figure 1: Therapeutic antibody definitions
Figure 2: Cancer monoclonal antibody partnering since 2012
Figure 3: Active Cancer monoclonal antibody dealmaking activity since 2012
Figure 4: Cancer monoclonal antibody partnering by deal type since 2012
Figure 5: Cancer monoclonal antibody partnering by disease type since 2012
Figure 6: Cancer monoclonal antibody deals with a headline value
Figure 7: Cancer monoclonal antibody deals with an upfront value
Figure 8: Cancer monoclonal antibody deals with a milestone value
Figure 9: Cancer monoclonal antibody deals with a royalty rate value
Figure 10: Top Cancer monoclonal antibody deals by value since 2012
Figure 11: Most active Cancer monoclonal antibody dealmakers since 2012
Figure 12: Online partnering resources
Figure 13: Forthcoming partnering events
  • Global Minocycline Hydrochloride Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 19-Jun-2018        Price: US 3480 Onwards        Pages: 111
    Minocycline Hydrochloride, also called minocycline HCL, is a broad-spectrum tetracycline antibiotic, and has a broader spectrum than the other members of the group. It is a bacteriostatic antibiotic, classified as a long-acting type. As a result of its long half-life it generally has serum levels 2-4 times that of the simple water-soluble tetracyclines. The CAS Number is 13614-98-7. Scope of the Report: This report focuses on the Minocycline Hydrochloride in global ......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Minocycline Hydrochloride Market 2018, Forecast to 2023
    Published: 19-Jun-2018        Price: US 4880 Onwards        Pages: 114
    Minocycline Hydrochloride, also called minocycline HCL, is a broad-spectrum tetracycline antibiotic, and has a broader spectrum than the other members of the group. It is a bacteriostatic antibiotic, classified as a long-acting type. As a result of its long half-life it generally has serum levels 2-4 times that of the simple water-soluble tetracyclines. The CAS Number is 13614-98-7. Scope of the Report: This report focuses on the Minocycline Hydrochloride in global ......
  • Global Antibodies Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 16-Jun-2018        Price: US 3480 Onwards        Pages: 133
    An antibody (Ab), also known as an immunoglobulin (Ig), is a large, Y-shaped protein produced mainly by plasma cells that is used by the immune system to neutralize pathogens such as pathogenic bacteria and viruses. The antibody recognizes a unique molecule of the pathogen, called an antigen, via the Fab's variable region. Scope of the Report: This report focuses on the Antibodies in global market, especially in North America, Europe and Asia-Pacific, South America,......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Antibodies Market 2018, Forecast to 2023
    Published: 16-Jun-2018        Price: US 4880 Onwards        Pages: 130
    An antibody (Ab), also known as an immunoglobulin (Ig), is a large, Y-shaped protein produced mainly by plasma cells that is used by the immune system to neutralize pathogens such as pathogenic bacteria and viruses. The antibody recognizes a unique molecule of the pathogen, called an antigen, via the Fab's variable region. Scope of the Report: This report focuses on the Antibodies in global market, especially in North America, Europe and Asia-Pacific, South America,......
  • 2015-2023 World Benign Prostatic Hyperplasia (BPH) Drugs Market Research Report by Product Type, End-User (Application) and Regions (Countries)
    Published: 16-Jun-2018        Price: US 2800 Onwards        Pages: 131
    Summary This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. Market Segment as follows: By Region / Countries - North America (U.S., Canada, Mexico) - Europe (Germany, U.K., France, Italy, Russia, Spain etc) - South America (Brazil, Argentina etc) - Middle East & Afri......
  • Global Caffeine Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 16-Jun-2018        Price: US 3480 Onwards        Pages: 132
    Caffeine is a bitter, white crystalline purine, methyl xanthine alkaloid, which is founded in coffee, tea, soft drinks, chocolate, kola nuts, and certain medicines. Unlike many other psychoactive substances, it is legal and unregulated in nearly all parts of the world. Scope of the Report: This report focuses on the Caffeine in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the mark......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Caffeine Market 2018, Forecast to 2023
    Published: 16-Jun-2018        Price: US 4880 Onwards        Pages: 129
    Caffeine is a bitter, white crystalline purine, methyl xanthine alkaloid, which is founded in coffee, tea, soft drinks, chocolate, kola nuts, and certain medicines. Unlike many other psychoactive substances, it is legal and unregulated in nearly all parts of the world. Scope of the Report: This report focuses on the Caffeine in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the mark......
  • Global Hyoscine-N-Butyl Bromide Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 15-Jun-2018        Price: US 3480 Onwards        Pages: 116
    Hyoscine-N-Butyl Bromideis obtained from a species of the plant genus Duboisia. It is mainly classified as an antispasmodic, which means that it is a drug used to suppress of muscle spasms, or involuntary contractions. It is used to treat pain and discomfort caused by abdominal cramps, menstrual cramps or other spasmodic activity in the digestive system. It is also effective at preventing bladder spasms. Scope of the Report: This report focuses on the Hy......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Hyoscine-N-Butyl Bromide Market 2018, Forecast to 2023
    Published: 15-Jun-2018        Price: US 4880 Onwards        Pages: 114
    Hyoscine-N-Butyl Bromideis obtained from a species of the plant genus Duboisia. It is mainly classified as an antispasmodic, which means that it is a drug used to suppress of muscle spasms, or involuntary contractions. It is used to treat pain and discomfort caused by abdominal cramps, menstrual cramps or other spasmodic activity in the digestive system. It is also effective at preventing bladder spasms. Scope of the Report: This report focuses on the Hy......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs